查詢結果分析
相關文獻
- Clinical Utility of Cutoff Index Adjustment in Hepatitis B Surface Antigen Detection
- B型肝炎表面抗原項目確認試驗的適合性評估
- 電穿孔法運用於COS-1細胞之基因轉移
- C型肝炎在雲嘉地區肝癌的重要性
- 利用震盪器培養家蠶細胞量產B型肝炎表面抗原蛋白之影響因素
- The Status of Serum Hepatitis B Virus DNA in Hbsag-Positive Hepatocellular Carcinoma
- B 型肝炎表面抗原帶原者肝硬化之多重危險因子研究
- 臺灣腎病變症候群病兒之血中B型肝炎表面抗原及其與腎臟病理類型之關係
- Effects of Nifedipine, Verapamil on Hepatic and Systemic Hemodynamics in Patients with HBsAg-Positive Cirrhosis:Comparison with Propranolol
- 101年B型肝炎表面抗體診斷試劑效能評估調查研究
頁籤選單縮合
| 題 名 | Clinical Utility of Cutoff Index Adjustment in Hepatitis B Surface Antigen Detection=B型肝炎表面抗原臨界值指數修正之臨床應用 |
|---|---|
| 作 者 | 古伯文; 甯孝真; 盧章智; 邱正堂; 許朝偉; 吳治慶; | 書刊名 | Journal of Biomedical & Laboratory Sciences |
| 卷 期 | 34:3 2022.09[民111.09] |
| 頁 次 | 頁133-140 |
| 分類號 | 415.5332 |
| 關鍵詞 | B型肝炎表面抗原; B型肝炎表面抗體; 確認試驗; 臨界值指數; Hepatitis B surface antigen; Hepatitis B surface antibody; Confirmatory assay; Cutoff index; |
| 語 文 | 英文(English) |
| 中文摘要 | 快速且正確進行 B 型肝炎表面抗原 (Hepatitis B surface antigen, HBsAg) 診斷在 B 型肝炎疾病控制上十 分重要。表面抗原及抗體 (Hepatitis B surface antibodies, anti-HBs) 同時陽性時,需加測確認試驗以確認 HBsAg 結果。在本研究之兩段實驗區間,各分析 35,053 與 49,206 例病患,其中 HBsAg 與 Anti-HBs 同時 陽性有 392 與 438 例,同占 1%。實驗一,392 病患中有 110 例 (28%) 其 HBsAg 臨界值指數低於 100, 經確認試驗,96 例 (87%) 為陽性。再經病歷審查為真陽性者共 76 例 (87%),其中臨界值指數介於 20 至 100 有 21 例,皆為真陽性(無偽陽性)。於實驗二,HBsAg 加測確認試驗之臨界值指數下修至 20,438 例中 65 (15%) 例符合加測標準,55 例 (86%) 確認試驗陽性,病例審查為真陽性者共 40 例 (83%)。加測標準 修正後之陽性預測率,實驗二為 83%近於實驗一之 87%,但須做確認試驗之檢體比例由 28%減至 15%, 具統計意義。經實驗證明,加測確認試驗之臨界值指數下修,並不影響陽性預測率。我們提供一合理且實 用之策略,去除非必要之確認,降低檢驗室工作量並增進報告時效。 |
| 英文摘要 | Rapid and accurate identification of HBsAg is critical for the management of hepatitis B. Here, the coexistence of hepatitis B surface antigen (HBsAg) and hepatitis B surface antibodies (anti-HBs) was observed in patients, and an additional antibody neutralization test was performed to confirm the presence of HBsAg. In this study, we enrolled 35,053 and 49,206 nonrepeat patients in two study periods, and the coexistence of HBsAg and anti-HBs was confirmed in 392 (1%) and 438 (1%) patients, respectively. In Study 1, 110 (28%) patients with HBsAg cutoff index (COI) values lower than 100 were subjected to confirmatory assays, and 96 (87%) patients were confirmed to be positive. Following medical chart review, 76 (87%) patients were identified as having HBsAg true-positive cases, including 21 patients with COI values of 20- 100. Because no false-positive results were found in patients with COI values of 20–100, we adjusted a cutoff criterion from 100 to 20 in Study 2. Among the 438 patients with the coexistence of HBsAg and anti-HBs, 65 (15%) patients with HBsAg COI values of less than 20 were subjected to confirmatory assays. Fiftyfive(86%) patients were confirmed to be positive. Medical records indicated that 40 (83%) patients were true-positive cases. The positive predictive values (PPV) of the confirmatory assay with two cutoff criteria (COI < 100 in Study 1 vs. COI < 20 in Study 2) were compared. Similar PPVs, 87% (Study 1) and 83% (Study 2), were observed. A significant reduction in the confirmatory test rates was identified (p <0.05, 15% in Study 2 vs. 28% in Study 1). In conclusion, we provide evidence of no changes in the PPV of the HBsAg confirmatory assay with adjusted HBsAg COI criteria. We reported a reliable and practical strategy to eliminate unnecessary confirmation and thus reduce workloads in the clinical laboratory and provide rapid diagnostic results. |
本系統中英文摘要資訊取自各篇刊載內容。